Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66 EUR | -2.22% |
|
-19.64% | -30.05% |
19/06 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | ![]() |
18/06 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | ![]() |
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2024 P/E ratio at 27.27 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.05% | 637.83Cr | - | ||
+7.23% | 22TCr | B | ||
+11.31% | 19TCr | B- | ||
+28.94% | 15TCr | B- | ||
+32.00% | 11TCr | A- | ||
-0.46% | 6.28TCr | A- | ||
+16.09% | 5.33TCr | B+ | ||
+0.94% | 4.88TCr | B+ | ||
-2.97% | 3.94TCr | A | ||
+1.23% | 3.57TCr | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFX Stock
- AFXA Stock
- Ratings Carl Zeiss Meditec AG